A new study has revealed that a new type of therapy can help modify patients T-cells into powerful tumor eliminating agents that can help leukemia sufferers stay cancer free for a year.
These results are the first to reveal in the way that gene transfer therapy can produce specialized T-cells which can protect the body form infections that can attack cancerous tumors in advance situations of chronic lymphocytic leukemia. This particular technique has assisted many patients who in the past have had little hope of survival to fend off their cancer illness and to keep it in remission, according to the New England Journal of Medicine. Senior author Carl June of the Abramson Cancer Center from the University of Pennsylvania stated that, “within three weeks, the tumors had been blown away and in a way was more violent that we every expected.” Researchers replaced a sample of the patients T-cells and genetically modified them to cling on to cells that express a certain kind of protein.
Scientist have also engineered the T-cells to begin triggering other T-cells to multiply the second that they attach themselves to a cancer cell thus bringing the death of it much faster.
Doctor Jung stated that, “we saw at least a 1,000 fold increase in the number of modified T-cells in each of the patients, and drugs don’t do that.” He has described the infused T-cells as serial killers. He also adds that,” on an average, each infused T-cells has led to the killing of thousands of tumor cells and have destroyed at least two pounds of tumors in each patient for the most part.”
Bone marrow transplants are the most common procedure for leukemia patients but they also carry a 20 % risk of death from the procedure and the survival rates have hovered at a mere 50%. Scientists are still trying to find out how long the treatment may withhold cancer from appearing. Some evidence has been found that after months of infusion the new cells had multiplied and were capable of continuing their seek and destroy duty against cancerous cells throughout a patient’s body. This treatment will also be used to analyze similar procedures that could target non-Hodgkin’s lymphoma and acute lymphocytic mesothelioma cancer, ovarian and pancreatic cancer cells.